Agendia's Pipeline, Test Business Could Benefit From Companion-Dx Deal with AstraZeneca, NKI

CEO Bernhard Sixt said the collaboration may "benefit" ColoPrint, Agendia's in-development colorectal cancer test, by helping to discover a "tentative molecular subtype signature for the test."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.